Embassy Developments Q1 FY27 pre-sales up 338% YoY at about Rs 868 cr

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

EMBDL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.0%Reaction day

₹65.10

prior close

₹65.99

announcement price

In-mkt

timing

Nifty Microcap 250market-0.2%-0.8% vs market

Residential Commercial Projects peers, median of 65sector-0.4%-0.6% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.6 pts less than its Residential Commercial Projects peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.2

10m

+0.8

15m

+0.7

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.0-0.2-0.8-0.4-0.6

Next day

-4.8+0.2-5.0-1.2-3.6

-4.2+0.4-4.5+0.1-4.3

-5.1+0.4-5.5+0.2-5.3

-3.4+0.6-3.9+0.2-3.6

-3.7+0.9-4.6-0.4-3.3

-3.1+0.9-4.0-0.5-2.6

15d

-8.9+0.9-9.8-2.1-6.8

-14.9+2.3-17.3-4.8-10.1

-14.7-1.1-13.6-8.3-6.4

—————

UpDownMarket · Nifty Microcap 250Sector · Residential Commercial Projects peers, median of 65Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Embassy Developments reported Q1 FY27 pre-sales of about Rs 868 crore, up 338% year-on-year from Rs 198 crore. Collections rose 54% YoY to about Rs 496 crore. The company received RERA approval for Embassy Terazza in Juhu, Mumbai with GDV exceeding Rs 3,000 crore. Board approved Rs 363 crore preferential warrants to promoters at Rs 111.51 per share, an 80% premium, with conversion committed within 6 months. On track for FY27 guidance of Rs 6,000 crore owned plus Rs 2,000 crore DM pre-sales.

Likely market impact

Strong quarterly performance and promoter-backed capital infusion signal positive outlook; potential dilution from warrant conversion remains a watch point.